Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Total Liabilities readings, the most recent being $219.6 million for Q1 2026.

  • On a quarterly basis, Total Liabilities rose 54.82% to $219.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $219.6 million, a 54.82% increase, with the full-year FY2025 number at $196.0 million, up 37.93% from a year prior.
  • Total Liabilities hit $219.6 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $196.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $219.6 million in Q1 2026 to a low of $52.8 million in Q1 2023.
  • Median Total Liabilities over the past 5 years was $87.8 million (2024), compared with a mean of $112.2 million.
  • Biggest five-year swings in Total Liabilities: soared 95.68% in 2022 and later decreased 18.47% in 2023.
  • Kiniksa Pharmaceuticals International's Total Liabilities stood at $63.5 million in 2022, then soared by 37.72% to $87.5 million in 2023, then surged by 62.45% to $142.1 million in 2024, then surged by 37.93% to $196.0 million in 2025, then grew by 12.02% to $219.6 million in 2026.
  • The last three reported values for Total Liabilities were $219.6 million (Q1 2026), $196.0 million (Q4 2025), and $177.0 million (Q3 2025) per Business Quant data.